Spinraza denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for spinraza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Apply Quantity Limits to Spinraza

Spinraza (nusinersen) is administered on a specific loading and maintenance dosing schedule established in the FDA-approved prescribing information. Aetna's quantity-limit denials for Spinraza typically arise when the number of doses requested in a given period exceeds what Aetna's policy recognizes as the standard maintenance schedule, or when the policy has not been updated to reflect the treating specialist's prescribed regimen.

The FDA-approved dosing schedule is the controlling clinical reference. If your prescribed regimen matches the FDA label, this denial should be straightforwardly appealable by providing the label and confirming the prescribed schedule.

## Federal Appeal Rights

• ACA §2719 external review: Available for non-grandfathered plans; approximately four months from denial to request. The external reviewer applies an independent clinical standard and will assess whether the prescribed quantity is consistent with the FDA label and medical practice.
• ERISA §503: Employer-plan members can request the exact policy language and quantity limit applied, enabling a precise rebuttal.
• Expedited review: Given SMA's progressive nature, treatment delays from quantity-limit disputes warrant expedited appeal. Document the urgency with the treating specialist's input.

## Documentation to Gather

• FDA prescribing information: The current FDA-approved label for Spinraza specifying the approved dosing schedule. This is the primary reference for what quantity is medically standard.
• Prescriber order: The treating specialist's prescription or order, with the dose schedule explicitly stated, confirming it aligns with the FDA-approved regimen.
• Specialist justification letter: If the requested schedule deviates from the most common maintenance schedule (for example, more frequent dosing for a specific clinical reason), a letter from the treating neuromuscular specialist explaining the medical basis.
• Clinical status documentation: Notes documenting the patient's current functional and clinical status, supporting the medical necessity of ongoing therapy at the prescribed frequency.
• Prior authorization history: Any prior approvals of Spinraza for this patient, showing a consistent dosing pattern previously accepted by Aetna.

## Criteria-Mapping Framework

Request Aetna's quantity-limit policy for Spinraza in writing. Build a response addressing the specific limit applied:

| Aetna Quantity Limit Applied | Rebuttal | |---|---| | Doses per [period] limited to [policy number] | FDA-approved schedule (label attached) supports [prescribed schedule] | | Maintenance phase criteria | Specialist confirms patient is in [loading/maintenance] phase per label | | [Any other quantity criterion] | [Specific response and chart citation] |

If Aetna's quantity limit matches the FDA label and the denial is due to a timing or administrative discrepancy, a brief corrective submission — rather than a full appeal — may resolve it faster. Confirm with the specialty pharmacy whether the claim was billed with the correct procedure code and date of service before filing the full appeal.